Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CCI-779 in Malignant Glioma
NCT00022724Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Aug 2001
- Primary completion
- May 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of temsirolimus in malignant glioma (2 arms), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoints: Maximum Tolerated Dose, Safety Profile and 3 more. Started Aug 2001; status: completed.
02
Drugs
temsirolimus
03
Conditions
malignant glioma
Beyond the preview
Go deeper on NCT00022724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00022724.